|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-6-4
|
|
pubmed:abstractText |
IFN-producing killer dendritic cells (IKDC) were initially described as B220(+)CD11c(+)CD3(-)NK1.1(+) tumor-infiltrating cells that mediated part of the antitumor effects of the combination therapy with imatinib mesylate and IL-2. In this study, we show their functional dependency on IL-15 during homeostasis and inflammatory processes. Trans-presentation of IL-15 by IL-15Ralpha allows dramatic expansion of IKDC in vitro and in vivo, licenses IKDC for TRAIL-dependent killing and endows IKDC with immunizing potential, all three biological attributes not shared by B220(-)NK cells. However, IL-15 down-regulates the capacity of IKDC to induce MHC class I- or II-restricted T cell activation in vitro. Trans-presentation of IL-15 by IL-15Ralpha allows IKDC to respond to TLR3 and TLR4 ligands for the production of CCL2, a chemokine that is critical for IKDC trafficking into tumor beds (as described recently). We conclude that IKDC represent a unique subset of innate effectors functionally distinguishable from conventional NK cells in their ability to promptly respond to IL-15-driven inflammatory processes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
pubmed-author:BonmortMathieuM,
pubmed-author:BosisioDanielaD,
pubmed-author:BulanovaElenaE,
pubmed-author:Bulfone-PausSilviaS,
pubmed-author:ChaputNathalieN,
pubmed-author:GeissmanFredericF,
pubmed-author:JacobsBenediktB,
pubmed-author:JalilAbdelaliA,
pubmed-author:LouacheFawziaF,
pubmed-author:MignotGregoireG,
pubmed-author:RyffelBernardB,
pubmed-author:SozzaniSilvanoS,
pubmed-author:UllrichEvelynE,
pubmed-author:ZitvogelLaurenceL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
180
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7887-97
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:18523252-Animals,
pubmed-meshheading:18523252-Antigen Presentation,
pubmed-meshheading:18523252-Cell Line, Tumor,
pubmed-meshheading:18523252-Cell Proliferation,
pubmed-meshheading:18523252-Cell Separation,
pubmed-meshheading:18523252-CpG Islands,
pubmed-meshheading:18523252-Cross-Priming,
pubmed-meshheading:18523252-Dendritic Cells,
pubmed-meshheading:18523252-Female,
pubmed-meshheading:18523252-Homeostasis,
pubmed-meshheading:18523252-Immunophenotyping,
pubmed-meshheading:18523252-Interferons,
pubmed-meshheading:18523252-Interleukin-15,
pubmed-meshheading:18523252-Interleukin-15 Receptor alpha Subunit,
pubmed-meshheading:18523252-Killer Cells, Natural,
pubmed-meshheading:18523252-Melanoma, Experimental,
pubmed-meshheading:18523252-Mice,
pubmed-meshheading:18523252-Mice, Inbred C57BL,
pubmed-meshheading:18523252-Mice, Knockout,
pubmed-meshheading:18523252-Mice, Transgenic
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions.
|
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale U805, Center of Clinical Investigations CBT507, Institut Gustave Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
